Elevated level of mitochondrial reactive oxygen species via fatty acid β-oxidation in cancer stem cells promotes cancer metastasis by inducing epithelial–mesenchymal transition
Cancer stem cells (CSCs) play a critical role in tumor development and progression and are involved in cancer metastasis. The role of reactive oxygen species (ROS) in CSCs and cancer metastasis remains controversial. The aim of the present study was to investigate the correlation between ROS level of CSCs and cancer metastasis and to explore the possible underlying molecular mechanisms.
Four different cell lines were used to isolate tumor spheres and to analyze intrinsic properties of tumor sphere cells including proliferation, self-renewal potential, differentiation, drug-resistance and cancer metastasis in vitro and in vivo. ROS assays were used to detect the intracellular ROS level of tumor spheres cells. Gene expression analysis and western blot were used to investigate the underlying mechanisms of ROS in regulating cancer metastasis.
Tumor spheres possessed the characteristic features of CSCs, and ROS-high tumor spheres (RH-TS) displayed elevated mitochondrial ROS level exclusively drove metastasis formation. The gene expression analysis showed elevated fatty acid β-oxidation, downregulation of epithelial marker upregulation of mesenchymal markers, and the activation of MAP kinase cascades. Furthermore, 14 up-regulated genes in RH-TS cells were associated with reduced overall survival of different cancer patients.
Our findings demonstrate that CSCs characterized by elevated mitochondrial ROS level potentiate cancer metastasis. Mechanistically, elevated mitochondrial ROS via fatty acid β-oxidation, activates the MAPK cascades, resulting in the epithelial-mesenchymal transition (EMT) process of RH-TS cells, thereby potentiating caner invasion and metastasis. Therefore, targeting mitochondrial ROS might provide a promising approach to prevent and alleviate cancer metastasis induced by RH-TS cells.
KeywordsCancer stem cells Tumor sphere ROS Cancer metastasis Mitochondria Epithelial-mesenchymal transition
Cancer Stem Cells
- MitoSOX Red
MitoSOX TM Red mitochondrial superoxide indicator
ROS-High Tumor Spheres
ROS-Low Tumor Spheres
Reactive oxygen species
Although only 0.01–0.02% of potential cancer cells succeed in metastatic colonization, more than 90% of mortality from cancer is attributable to metastases [1, 2]. It is vital to define and separate these life-threatening metastatic cancer cells. As tumors progress, intra-tumor heterogeneity arises through cycles of mutation and clonal selection. Most tumors contain a subpopulation of highly tumorigenic cells, known as cancer stem cells (CSCs) or tumor-initiating cells (TICs). CSCs, an integral part of tumor mass, are generally supposed to be a sub-population of quiescent cells endowed with self-renewal and differentiation properties and strongly influence tumor propagation and cancer metastasis [3, 4, 5]. The discovery of cancer stem cells has significantly changed our concepts about the mechanisms of multi-step tumorigenesis and metastasis, since these self-renewing cells (or closely related progenitor cells), rather than the bulk populations of cancer cells, may be the objects of genetic alteration and clonal selection.
Early reports suggested that CSCs were mostly homogeneous, which were commonly characterized on the basis of the expression profiles of their markers. However, subsequent works revealed an unexpected heterogeneity within the CSCs compartments from different tumors, including breast cancer [6, 7, 8], melanoma , colorectal cancer , and glioblastoma . Intra-tumor heterogeneity allows CSCs to differentiate into multiple tumor cell types and contributes to the resistance of the targeted therapy. Accordingly, strategy which specifically targets and kills metastasis-related CSCs represents one of the most important challenges for tumor eradication.
Recently, targeting cancer via reactive oxygen species (ROS)-based mechanisms has been argued as a radical therapeutic approach . Cancer cells frequently display higher level of ROS than normal cells, implicating that targeting cancer via enhancing ROS might selectively kill cancer cells. However, the role of ROS in cancer metastasis has been of considerable debate. Several studies concluded that ROS, as signaling molecules, facilitated CSCs self-renewal and expansion [13, 14], stimulated cell invasiveness , and potentiated tumor progression [16, 17]. Nonetheless, increased ROS level was also reported to be detrimental for other stem cells such as hematopoietic stem cells (HSCs)  and inhibit cancer metastasis . The illusive roles of ROS in cancer metastasis might partially result from heterogeneity of the CSCs.
As hypothesized, CSCs might divide slowly and maintain a lower metabolic state and lower ROS level than non-CSCs [20, 21, 22]. However, it remains unknown whether all CSCs are equally capable of metastasis formation and producing low ROS level as a homogeneous population. Tumor spheres characterized by suspension growth in culture medium could efficiently maintain CSCs without restriction to a particular surface phenotype and have been widely used to enrich CSCs in cancer research [11, 23, 24, 25]. In this study, we isolated tumor spheres from 4 different cancer cell lines including 4 T1, HT29, HCT116, and SW480, and investigated the correlation between ROS level of tumor spheres and cancer metastasis. The objectives of our study are: (1) To determine whether the tumor spheres are composed of a homogeneous population with lower ROS level as compared to non-cancer stem cells? (2) To examine what are the underlying mechanisms of ROS in regulating cancer metastasis?
Four cell lines (4 T1, SW480, HCT116 and HT29) were purchased from the Cell Bank of Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). 4 T1 cells were maintained in complete RPMI-1640 (Life Technologies). SW480 cells were cultured in Leibovitz’s L-15 medium. HCT116 and HT29 cells were maintained in complete McCoy’s 5a Medium. Culture mediums were all supplemented with 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin, and 2 mM L-glutamine in a 5% CO2 environment at 37 °C. The authentication testing of cell lines have been performed by Shanghai Biowing Applied Biotechnology Co., Ltd. All the cell lines used in our study matched the standards recommended for cell lines authentication. All the cells were mycoplasma-free and routinely checked with the PCR Mycoplasma detection kit (K0103, HuaAn Biotechnology).
Establishment of tumor spheres, ROS-high tumor spheres (RH-TS) and ROS-low tumor spheres (RL-TS)
To induce tumor spheres in 4 T1, SW480, HCT116, and HT29 cell lines, cells were dissociated enzymatically using 0.05% Trypsin-EDTA solution, diluted to a density of 2 × 104/mL, and then plated in non-coated petri dishes. Cells were grown in serum-free DMEM/F12 medium containing 40 ng/mL basic fibroblast growth factor (bFGF) and 20 ng/mL epidermal growth factor (EGF) (both from PeproTech), B-27® Serum-Free Supplement (17,504,044, Gibco), N-2 Supplement (17,502,048, Gibco), and 4 μg/mL Heparin sodium salt (H3393, Sigma-Aldrich). The cells were cultured in an incubator at 37 °C with 5% CO2. Tumor spheres collected after ~ 14 days culture were used for further study. We further measured the cellular ROS level represented by DCFH-DA of tumor spheres of 4 T1 cells, HCT 116 cells, SW480 cells and HT29 cells using confocal microscope and flow cytometry. We found that tumor sphere cells were composed by two major subpopulations of cells on the basis of ROS concentration, with the ROS high-tumor spheres cells (RH-TS) and ROS low-tumor spheres cells (RL-TS). We used flow cytometry to separate and collect RH-TS cells and RL-TS cells for further studies.
3-D culture, frozen section, immunofluorescence, or hematoxylene and eosin staining
We used the 3 Dimensions (3D) on-top assay to analyze the colony morphology of RH-TS cells and RL-TS cells. Generally, the 8-well glass with pre-chilled culture surface (Millicell EZ SLIDE 8-well glass, PEZGS 0816) was covered with 150 μL per well Matrigel™ Basement Membrane Matirx (BD 356234), incubated for 15 min at 37 °C to allow the Matrigel to solidify. Cells at a concentration of ~ 100 cells/well were cultured in the 8-well glass with the Matrigel-medium mixture (10% volume of Matrigel) to the plated culture and the mixture was replaced every 2 days. After 10–14 days culture, the 3D cell clones were harvested for further analysis. For frozen section, the 3D clones were embedded in O.C.T. Compound (4583, SAKURA Tissue-Tek). Five μm sections were cut on a cryostat (Leica CM1950; Leica, Wetzlar, Germany) and post-fixed in ethanol: acetone fixation solution (with a volume of 3:1 ethanol: acetone) for 10 min at room temperature. For immunofluorescence, frozen sections were permeabilized with 0.2% Triton X-100 for 15 min, blocked with 3% BSA for 1 h and incubated with anti-EpCAM antibody (1:1000 dilution of ab71916, Abcam, UK) or anti-TP63 antibody (1:50 dilution of ab735, Abcam, UK) according to the protocols of the suppliers. All post-fixed sections were mounted and viewed under Zeiss LSM 710 laser confocal microscope (Carl Zeiss, Jena, Germany). Moreover, frozen sections stained with hematoxylene and eosin (HE) were evaluated and photographed with a Nikon Eclipse 50i microscope equipped with NIS-Elements software (version 3.22).
Tumor sphere cells (red fluorescence, loaded with 10 μM SNARF™-1) and parental cells (green fluorescence, loaded with 5 μM CFDA SE) were treated with drugs including cisplatin (5 μg/L), methotrexate (MTX, 10 μg/L), doxorubicin (Dox, 10 μg/L), taxel (50 μg/L), Etoposide (10 μg/L), or VCR (5 μg/L). After 2 days of incubation, the cells were observed under a Zeiss LSM710 laser confocal microscope (Carl Zeiss, Germany) equipped with Zen software to process the images.
For immunofluorescence of tumor cells, 4 T1 cells grown on cover slip and primary tumor spheres which were isolated from 4 T1 parental cells and then centrifuged onto glass slides were fixed with 3.7% paraformaldehyde for 15 min and permeabilized with 0.2% Triton X-100 for 15 min at room temperature. The cells were blocked with 3% BSA for 1 h and incubated with anti-CD24 antibody (1:100 dilution of ab25657), anti-CD44 antibody (1:100 dilution of ab119863), anti-EpCAM antibody (1:1000 dilution of ab71916), anti-TP63 antibody (1:50 dilution of ab735), anti-ASMA antibody (1:200 dilution of ab3280), or anti-CD49f antibody (1:100 dilution of ab95703), according to the protocols of the suppliers. Nuclei were counterstained with DAPI. All antibodies were purchased from Abcam. All post-fixed sections were mounted and viewed under Zeiss LSM 710 laser confocal microscope (Carl Zeiss, Jena, Germany) equipped with Zen software to process the image.
For immunofluorescence of tumor tissues, anti-EpCAM and anti-TP63 antibodies were used to evaluate the differentiation of RH-TS cells in the tumor samples. Briefly, tumor tissue sections were permeabilized with 0.2% Triton X-100 for 15 min, blocked with 3% BSA for 1 h and incubated with anti-EpCAM antibody (1:1000 dilution of ab71916, Abcam, UK) or anti-TP63 antibody (1:50 dilution of ab735, Abcam, UK) according to the protocols of the suppliers. All post-fixed sections were mounted and viewed under Zeiss LSM 710 laser confocal microscope (Carl Zeiss, Jena, Germany).
Measurement of cellular reactive oxygen species
Cellular ROS was detected using specific ROS probes by confocal microscope and flow cytometry. For flow cytometric measurement, cells were incubated with 2′,7′-Dichlorodihydrofluorescein diacetate (DCFH-DA, 10 μM, Sigma, D6883) or dihydroethidium (DHE, 5 μM, Sigma, D7008) for 30 min at 37 °C, after which the cells were washed and suspended in ice-cold PBS and analyzed for fluorescence intensity using a 485 nm excitation beam (FACS ArrayBioanalyzer, BD biosciences). Flow Jo 7.6 was utilized to quantify the mean fluorescence intensity. For confocal measurement, ROS measurement was assayed by DCFH-DA, DHE, MitoSOX TM Red mitochondrial superoxide indicator (MitoSOX Red, Invitrogen, M36008), or 4-amino-5-methylamino-29,79-difluorofluorescein (DAF-FM, Sigma, D2321), according to manufacturer’s instruction. Briefly, cells were loaded with DCFH-DA (10 μM for 30 min), DHE (5 μM for 30 min), MitoSOX Red (2.5 μM for 10 min), or DAF-FM (10 μM for 30 min), washed with ice cold HBSS (Hank’s Balanced Salt Solution, pH 7.2), and then observed under a Zeiss LSM710 laser confocal microscope (Carl Zeiss, Germany) equipped with Zen software to process the images.
In vivo metastatic assay
BALB/c female mice and nude mice (4–5 weeks old) were obtained from animal experimental center of Zhejiang University of Traditional Chinese Medicine. Nude mice were housed in a standard polypropylene cage, housed in groups of five and given five days to acclimate to the housing facility. Environmental conditions were maintained at a temperature of 21 °C ± 2 °C, humidity of 55% ± 10%, and a 12:12 light:dark cycle. Animals were housed in 595 × 380 × 200 mm cages (Techniplast UK, 1354G Eurostandard Type IV) with food and water provided ad libitum. During housing, animals were monitored twice daily for health status. No adverse events were observed.
BALB/c mice were used to analyze 4 T1 cells, and nude mice were used to analyze the other three types of cancer cells. Mice were randomly inoculated with parental cells (~ 10,000 cells per mouse), tumor sphere cells (~ 10,000 cells per mouse), RH-TS cells (~ 10,000 cells per mouse), or RL-TS cells (~ 10,000 cells per mouse). Tumor spheres, RH-TS, and RL-TS were dissociated enzymatically using 0.05% Trypsin-EDTA solution, and counted. To analyze the differentiation ability of 4 T1 tumor sphere in vivo and avoid the influence of the murine breast tissue on cell differentiation, we inoculated one tumor sphere per Balb/C mouse subcutaneously. To analyze the cancer metastasis ability of tumor sphere in vivo, 4 T1 cells and its derived tumor spheres, RH-TS and RL-TS cells were orthotopically inoculated into the mammary fat pad of female BALB/c mice, and HCT116 cells, SW480 cells, HT29 cells and their derived tumor sphere, RH-TS and RL-TS cells were inoculated subcutaneously into the right flank of nude mice. Tumor volume was calculated using the formula V = (L × W2) × 0.5, where L and W equal mid-axis length and width, respectively. On the day of sacrifice, the mice were anesthetized with penobarbital sodium, pulmonary metastases were scored by counting the macroscopic metastatic nodules. For hepatic metastasis, sections were stained with H&E and examined microscopically. The incidence of hepatic metastasis was quantified by counting the total tissue area per liver section (D1) and metastasis present in the same area (D2). The metastatic index was calculated by the ratio D2/D1 . The relative area of metastases was measured using the Image J 1.45S software (NIH). All procedures were carried out in accordance with the Animals (Scientific Procedures) Act, 1986 (UK) (amended 2013). A completed ARRIVE guidelines checklist is included in Additional file 1: Checklist S1.
The whole expression files of 4 T1 parental cells, RH-TS cells, and RL-TS cells were investigated by using mRNA-Seq experiments performed by Novogene (Beijing, China). mRNA-seq library is prepared for sequencing using standard Illumina protocols. Gene Ontology (GO) enrichment analysis of differentially expressed genes was implemented by the cluster Profiler R package, in which gene length bias was corrected. GO terms with corrected P value less than 0.05 were considered significantly enriched by differential expressed genes. The statistical enrichment of differential expression genes in KEGG pathways was performed by the cluster Profiler R package.
To validate the gene chip data, we determined the expression of the following genes with real-time PCR. The procedure is described in detail in the Supporting information, Supplementary materials and methods.
Western blot analysis
The procedure is described in detail in the Supporting information, Supplementary materials and methods.
Calculation of NAD/NADH ratio
We measured the free NADH/NAD+ ratio as previously described by Sun F et al. . Briefly, the cytosolic lactate and pyruvate concentration were determined by HPLC. NAD/NADH was estimated by the L/P ratio and the equation of the chemical equilibrium which is reported by Williamson et al. Apparent Keq = [pyruvate] eq [NADH] eq. [H+]/ ([Lactate] eq [NAD]eq) = 1.11 X 10− 11, where pH is 7.0, If LDH catalyzed reaction is allowed to proceed to equilibrium, the final products and reactants could be expressed by the equation: Apparent Keq = Keq [H+], where Keq = [pyruvate] eq [NADH]eq/([Lactate] eq [NAD]eq) = 1.11 X 10− 4, or [NAD]/[NADH] = [pyruvate]eq/(Keq [Lactate]eq).
Transmission electron microscopy
Cells were fixed in 2.5% glutaraldehyde in 0.1 M sodium phosphate buffer (pH 7.4) overnight. The samples were treated with 1.5% osmium tetroxide, dehydrated with acetone, embedded in durcupan resin, post-stained with lead citrate and examined in a TECNAI 10 electron microscope (Philips, The Netherlands) at 60 kV.
Kaplan-Meier plots summarized results from analysis of correlation between mRNA expression level and patient survival from Human Protein Atlas database (http://www.proteinatlas.org), using best separation. Patients were divided based on level of expression into one of the two groups “low” or “high”. The 5-year survival for patients with high expression, 5-year survival for patients with low expression and log-rank P value are displayed. For glioma, 3-year survival is shown.
All data were analyzed using the InStat software (GraphPad, CA, USA) and displayed as mean ± SD. Two-tailed Student’s t-test was used for statistical analysis, and significance was defined at *** p<0.001, ** p<0.01, * p<0.05.
The cancer stem cell features of tumor spheres
We then analyzed the surface markers of tumor sphere cells by immunofluorescence with a panel of markers according to Pece et al. . The tumor sphere cells isolated from 4 T1 parental cells were CD44 + CD24-, while parental cells were CD44 + CD24+ (Fig. 1c). Moreover, tumor sphere cells expressed higher CD49f and lower ASMA than parental cells, while both parental cells and tumor sphere cells were EpCAM+TP63- (Fig. 1c). We further measured the expression of CD24 and CD44 by sorting. Most tumor sphere cells were CD44 + CD24-, while only 1.16 ± 0.95% parental cells were CD44 + CD24- (Fig. 1d). It is worthy pointing out that both parental cells and tumor sphere cells were not homogenous because the labeling intensity differed markedly, such as the CD44 and CD24 fluorescent intensity. Increasing evidence has demonstrated that Lgr5 marks a population of colon cancer CSCs. To study whether tumor spheres isolated from colon cancer cells possessed CSCs features, we examined the Lgr 5 expression in tumor spheres. As shown in Additional file 2: Figure S1, tumor spheres of HCT116 cells, SW480 cells, and HT29 cells were all Lgr 5+.
We next used 3D culture methods to analyze the differentiation ability of tumor spheres in vitro. Under 3D culture, tumor sphere cells formed acinar-like colonies containing both epithelial (EPCAM positive cells) and myoepithelial cells (TP63 positive cells) (Fig. 1e). To analyze the differentiation ability of 4 T1 tumor sphere in vivo and avoid the influence of the murine breast tissue on cell differentiation, we inoculated one tumor sphere per Balb/C mouse subcutaneously. It showed that xenotransplantation of tumor spheres subcutaneously reproducibly formed tumors. Of note, the mammary epithelium-like structure with differentiation markers (both EPCAM and TP63) was observed in the xenografts generated by tumor sphere cells (Fig. 1f). These data suggested that tumor sphere cells have the differentiation ability in vitro and in vivo.
Furthermore, we measured the drug-resistant ability of tumor spheres. As shown in Fig. 1g and Additional file 2: Figure S2, tumor sphere cells labeled with SNARF™-1 (red fluorescence) were obviously more resistant to anticancer drugs, such as cisplatin, methotrexate (MTX), doxorubicin (Dox), etoposide and vincristine (VCR) than parental cells labeled with CDFA SE (green fluorescence).
We also sorted out ROShigh cells with the same ROS level represented by DCFH-DA as RH-TS cells from 4 T1 parental cells by FCM (Additional file 2: Figure S3a). Using limiting dilution assay, we observed that ROShigh cells produced significantly more tumor sphere clones than ROSlow cells, but significantly less tumor sphere clones than RH-TS cells (Additional file 2: Figure S3b). The results suggested that ROShigh cells isolated from parental cells also had some feature of CSCs.
Taken together, our data revealed that tumor spheres possessed the characteristic features of CSCs, such as a high capacity of self-renewal, differentiation, and drug-resistance.
RH-TS exclusively drive metastases formation
We have demonstrated that hydrogen peroxide (H2O2) induced a high oxidative stress but permits cancer cells growth . Recently, Wang et.al reported that cellular ROS promoted cancer cell metastasis in vitro . To clarify whether ROS promote cancer cell invasion, we used Transwell invasion assays to analyze the invasion ability of 4 T1 cells with or without H2O2. As shown in Additional file 2: Figure S8, 4 T1 cells exhibited higher invasion ability with incubation of 0.1 mM H2O2.
Collectively, our data showed that tumor spheres have higher capacity of metastasis compared to the parental cells, in which RH-TS cells are the exclusive cell population responsible for the metastasis.
Level of mitochondrial ROS is elevated significantly in RH-TS
Metabolic remodeling of RH-TS contributes to an elevated mitochondrial ROS level
MAPK cascades and the epithelial-mesenchymal transition are predicted to be downstream of elevated mitochondrial ROS
TWIST1, TWIST2, SNAI1, and SNAI2 are EMT activators. MMPs can also induce EMT through multiple different signaling pathways [36, 37]. Collectively, our data demonstrated that elevated ROS level, especially the mitochondrial ROS level, activated the p38 MAPK signaling pathway, resulting in the EMT of RH-TS cells, and potentiating caner invasion and metastasis (Fig. 7c).
Fourteen up-regulated genes in RH-TS correlate to survival in cancer patients
Here, we demonstrated that the tumor spheres possessed the intrinsic properties of CSCs and were composed by two heterogeneous populations of cells: RH-TS and RL-TS. The RH-TS cells exhibited elevated mitochondrial ROS level and promoted metastasis formation. RH-TS cells were also characterized by upregulated expression of genes in fatty acid β-oxidation, MAP kinase cascades, and EMT. Moreover, 14 up-regulated genes in RH-TS cells were associated with poor overall survival in different types of cancers.
The redox status specifically in CSCs and its role in cancer metastasis are controversial. Belle et al. demonstrated that high endogenous ROS levels promote the self-renewal and neurogenesis in proliferative neural stem cells . Myant et al. showed that ROS accumulation becomes critical for human colorectal CSCs transformation and tumor initiation . Ishikawa et al. indicated that increased mitochondrial ROS could contribute to tumor progression by enhancing the metastatic potential of tumor cells . However, Ito et al. showed that higher ROS levels limit the lifespan of stem cells such as hematopoietic stem cells . Dong et al. reported that a metabolic switch to glycolysis following loss of fructose-1,6-biphosphatase, which inhibits oxygen consumption and ROS production, is required for the development of basal-like breast cancer [19, 42]. The role of ROS in cancer metastasis remains in great flux, partially because of the heterogeneity of CSCs. Recently, strands of evidence converge on the conclusion that redox homeostasis is the linchpin for CSCs in self-renewal, differentiation, and cancer metastasis. Furthermore, ROS play an important role in determining the fate of stem cells in a concentration-dependent manner. It is known that the intracellular ROS levels oscillate with changes in metabolic activity, and the mitochondria, as the metabolic center of mammalian cells, have been considered to be the major source of cellular-derived ROS because most cellular O2 consumption occurs as a result of mitochondrial ETC activity. Thus, the mitochondria might play a central role in ROS-mediated cancer metastasis. Indeed, emerging evidence has demonstrated the pivotal roles of mitochondria and mitochondrial ROS in cellular redox homeostasis and cancer metastasis [43, 44]. Therefore, mitochondrial ROS have been suggested to be novel targets for cancer therapy [45, 46]. Here, we showed that RH-TS cells displayed higher mitochondrial ROS levels and increased cancer metastasis than RL-TS cells. RH-TS cells elevated fatty acid β-oxidation resulting in an increased NADH level, oxygen consumption of mitochondrial ETC, and ROS production. These results suggest that fatty acid β-oxidation may be a therapeutic target, and the underlying mechanisms of broader involvement of fatty acid β-oxidation in RH-TS cells might be a focus of future investigations. Indeed, fatty acid β-oxidation has recently been shown to contribute to mitochondrial spare respiratory capacity and promote the stemness and chemoresistance of breast CSCs .
Moreover, it has been established recently that endogenous ROS function as second messengers to stimulate CSCs self-renewal and metastasis via reversibly modulating redox-sensitive pathways. p38 MAPK, possessing a reactive cysteine residue which can be activated by ROS via oxidation, is considered to be redox sensors and works as a mediator of ROS-regulated CSCs metastasis. Bhandari et al. argued that p38 MAPK, as a crucial regulator of redox sensor molecule, controlled the balance between MSC proliferation and differentiation . Invasion and metastasis begins with EMT, and several studies have documented that ROS play the crucial role in EMT through directly interacting with many critical EMT-inducing pathways [49, 50]. ROS production is vital to anoikis resistance for circulating tumor cells via the activation of PI3K/AKT and ERK signaling [51, 52]. Increasing evidence has shown that ROS play a role in creating a ‘soil’ in distal organs, setting up a supportive tumor environment for disseminated cancer cells [53, 54, 55]. Our data suggest that mitochondrial ROS might serve as signaling molecules linking fatty acid β-oxidation and EMT phenotype in RH-TS cells, and support the critical role of ROS and EMT in CSCs.
In addition to a role in redox regulation, ROS might also function to alter the epigenetic landscape, which plays a particularly pertinent role in regulating stem cell fate. Many metabolic intermediates are necessary substrates for the post-translational modifications of histones that together establish the epigenetic landscape of stem cells. As the activity of glycolysis and oxidative phosphorylation can directly influence ROS, leading to changes in the concentrations of various metabolic intermediates, this might represent a potential mechanism of ROS-mediated epigenetic regulation, albeit indirect. Given the different cellular oxidation capacities of metastatic CSCs, herein RH-TS, and normal stem cells, perhaps an effective redox targeting therapeutic strategy might be possible to kill metastatic CSCs.
In conclusion, we identified ROS-high CSCs as metastatic cancer cells, and the elevated mitochondrial ROS might be a useful biomarker of cancer metastasis. Inhibiting the key enzyme of β-oxidation of fatty acids such as CPT1A by pharmacological or genetic manipulations and diminishing cellular mitochondrial ROS level by mitochondrial-specific antioxidant agents such as SkQ1 might be a promising approach to prevent and alleviate cancer metastasis induced by RH-TS cells.
This work was supported by research grants from China Natural Sciences Foundation projects (81602516) to CPZ, (81773065) to JY and research grants from Zhejiang Provincial National Science Foundation of China (LY16H160019) to YZR, (LY16H160031) to LMS, (LQ17H160012) to CP, and (LY16H160030) to QD. The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data and in the writing of the manuscript.
Availability of data and materials
The datasets during and/or analyzed during the current study are available from the corresponding author on reasonable request.
CZ, ZD and YR. conceived the concept, designed the study, interpreted the data, and wrote the paper. CW, LS, CP, JY, ZD, JW, QD & CZ conducted the experiments and analyzed the data. All authors approved the final version of the manuscript.
The protocols for animal experiments were approved by the Committee of Animal Experimental Centre at the Zhejiang Chinese Medical University, and all procedures were carried out in accordance with the Animals (Scientific Procedures) Act, 1986 (UK) (amended 2013).
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 10.Myant KB, Cammareri P, McGhee EJ, Ridgway RA, Huels DJ, Cordero JB, Schwitalla S, Kalna G, Ogg EL, Athineos D, Timpson P, Vidal M, Murray GI, Greten FR, Anderson KI, Sansom OJ. ROS production and NF-kappaB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation. Cell Stem Cell. 2013;12:761–73.CrossRefGoogle Scholar
- 11.Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, Greve JM, Soriano RH, Gilmour LL, Rivers CS, Modrusan Z, Nacu S, Guerrero S, Edgar KA, Wallin JJ, Lamszus K, Westphal M, Heim S, James CD, VandenBerg SR, Costello JF, Moorefield S, Cowdrey CJ, Prados M, Phillips HS. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell. 2010;17:362–75.CrossRefGoogle Scholar
- 38.Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C, Sjostedt E, Asplund A, Olsson I, Edlund K, Lundberg E, Navani S, Szigyarto CA, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, Edqvist PH, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, Hamsten M, von Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen M, von Heijne G, Nielsen J, Ponten F. Proteomics Tissue-based map of the human proteome. Science. 2015;347:1260419.CrossRefGoogle Scholar
- 47.Wang T, Fahrmann JF, Lee H, Li YJ, Tripathi SC, Yue C, Zhang C, Lifshitz V, Song J, Yuan Y, Somlo G, Jandial R, Ann D, Hanash S, Jove R, Yu H. JAK/STAT3-regulated fatty acid beta-oxidation is critical for breast Cancer stem cell self-renewal and Chemoresistance. Cell Metab. 2018;27:1357.CrossRefGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.